🎉 M&A multiples are live!
Check it out!

Radiopharm Theranostics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Radiopharm Theranostics and similar public comparables like Pharming, Galapagos, and Benevolent AI.

Radiopharm Theranostics Overview

About Radiopharm Theranostics

Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.


Founded

2021

HQ

Australia
Employees

n/a

Financials

LTM Revenue $0.7M

LTM EBITDA -$26.0M

EV

$10.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Radiopharm Theranostics Financials

Radiopharm Theranostics has a last 12-month revenue of $0.7M and a last 12-month EBITDA of -$26.0M.

In the most recent fiscal year, Radiopharm Theranostics achieved revenue of $0.2M and an EBITDA of -$27.7M.

Radiopharm Theranostics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Radiopharm Theranostics valuation multiples based on analyst estimates

Radiopharm Theranostics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.2M $0.2M XXX XXX XXX
Gross Profit $6K $0.2M XXX XXX XXX
Gross Margin 3% 98% XXX XXX XXX
EBITDA -$19.6M -$27.7M XXX XXX XXX
EBITDA Margin -10669% -14732% XXX XXX XXX
Net Profit -$19.1M -$21.8M XXX XXX XXX
Net Margin -10377% -11567% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Radiopharm Theranostics Stock Performance

As of April 15, 2025, Radiopharm Theranostics's stock price is AUD 0 (or $0).

Radiopharm Theranostics has current market cap of AUD 53.7M (or $33.7M), and EV of AUD 17.2M (or $10.8M).

See Radiopharm Theranostics trading valuation data

Radiopharm Theranostics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$10.8M $33.7M XXX XXX XXX XXX $-0.03

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Radiopharm Theranostics Valuation Multiples

As of April 15, 2025, Radiopharm Theranostics has market cap of $33.7M and EV of $10.8M.

Radiopharm Theranostics's trades at 14.7x LTM EV/Revenue multiple, and -0.4x LTM EBITDA.

Analysts estimate Radiopharm Theranostics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Radiopharm Theranostics and 10K+ public comps

Radiopharm Theranostics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $10.8M XXX XXX XXX
EV/Revenue 20.3x XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E -1.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Radiopharm Theranostics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Radiopharm Theranostics Valuation Multiples

Radiopharm Theranostics's NTM/LTM revenue growth is 20%

Radiopharm Theranostics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Radiopharm Theranostics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Radiopharm Theranostics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Radiopharm Theranostics and other 10K+ public comps

Radiopharm Theranostics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 2% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 41% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 5141% XXX XXX XXX XXX
R&D Expenses to Revenue 5868% XXX XXX XXX XXX
Opex to Revenue 12338% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Radiopharm Theranostics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Radiopharm Theranostics M&A and Investment Activity

Radiopharm Theranostics acquired  XXX companies to date.

Last acquisition by Radiopharm Theranostics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Radiopharm Theranostics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Radiopharm Theranostics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Radiopharm Theranostics

When was Radiopharm Theranostics founded? Radiopharm Theranostics was founded in 2021.
Where is Radiopharm Theranostics headquartered? Radiopharm Theranostics is headquartered in Australia.
Who is the CEO of Radiopharm Theranostics? Radiopharm Theranostics's CEO is Mr. Riccardo Canevari.
Is Radiopharm Theranostics publicy listed? Yes, Radiopharm Theranostics is a public company listed on ASX.
What is the stock symbol of Radiopharm Theranostics? Radiopharm Theranostics trades under RAD ticker.
When did Radiopharm Theranostics go public? Radiopharm Theranostics went public in 2021.
Who are competitors of Radiopharm Theranostics? Similar companies to Radiopharm Theranostics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Radiopharm Theranostics? Radiopharm Theranostics's current market cap is $33.7M
What is the current revenue of Radiopharm Theranostics? Radiopharm Theranostics's last 12-month revenue is $0.7M.
What is the current EBITDA of Radiopharm Theranostics? Radiopharm Theranostics's last 12-month EBITDA is -$26.0M.
What is the current EV/Revenue multiple of Radiopharm Theranostics? Current revenue multiple of Radiopharm Theranostics is 14.7x.
What is the current EV/EBITDA multiple of Radiopharm Theranostics? Current EBITDA multiple of Radiopharm Theranostics is -0.4x.
What is the current revenue growth of Radiopharm Theranostics? Radiopharm Theranostics revenue growth between 2023 and 2024 was 2%.
Is Radiopharm Theranostics profitable? Yes, Radiopharm Theranostics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.